Marius Pharmaceuticals Supports AXYS 2023 Virtual Family Conference, Spotlighting KYZATREX™ for XY Chromosome Variations, such as Klinefelter’s Syndrome
20 juin 2023 08h30 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., June 20, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company specializing in therapies for hypogonadism or testosterone deficiency, announced today...
Marius Pharmaceuticals Announces Two Key Patents Related to KYZATREX™ in FDA Orange Book
09 juin 2023 10h00 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., June 09, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company focused on therapies designed for hypogonadism or testosterone deficiency, announced...
Global Polycystic Ovary Syndrome Treatment Market Report 2023: Sector is Expected to Reach $1.5 Billion by 2030 at a CAGR of 4.9%
01 juin 2023 11h23 HE
|
Research and Markets
Dublin, June 01, 2023 (GLOBE NEWSWIRE) -- The "Polycystic Ovary Syndrome Treatment Market, By Drug Class, By Distribution Channel, By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 -...
HealthEd Academy Reports On The Latest Ketogenic Diet Study And Its Link To Boosting Testosterone By 25%
20 déc. 2022 09h00 HE
|
HealthEd Academy
Clark, New Jersey, Dec. 20, 2022 (GLOBE NEWSWIRE) -- HealthEd Academy was created by fitness and bodybuilding expert, Steve Price, to share his vast experience and knowledge on how you can gain...
Base Healthcare Launches Innovative Platform for Men with Testosterone Deficiency
18 oct. 2022 08h00 HE
|
Base Healthcare
RALEIGH, N.C., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Base Healthcare today announced the official launch of its subscription-based men’s virtual health platform, which focuses on foundational health and...
CORRECTION -- Marius Pharmaceuticals Receives FDA Approval of KYZATREX™, an Oral Testosterone Replacement Therapy
21 sept. 2022 11h08 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., Sept. 21, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on August 2, 2022 by Marius Pharmaceuticals, please note that the correct number for reporting side...
Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction
18 août 2022 16h05 HE
|
Clarus Therapeutics Holdings, Inc.
Second quarter 2022 net revenue increased 46% year-over-year to $4.1 million Second quarter 2022 total prescription growth for JATENZO® increased 23% sequentially and increased 72% year-over-year ...
Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual Meeting
09 juin 2022 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., June 09, 2022...
Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)
18 mai 2022 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Clarus plans to list this patent...
Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results
12 mai 2022 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...